Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | GLS | O94925 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16117974 | 0.90 | KMT2A (0.46) | KMT2AMEN1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16117972 | 0.88 | KMT2A (0.44) | KMT2AMEN1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16822551 | 0.86 | KMT2A (0.46) | KMT2AMEN1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16117985 | 0.86 | KMT2A (0.46) | KMT2AMEN1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL27402995 | 0.84 | GPR119 (0.44) | KMT2AMEN1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL30961634 | 0.84 | GPR119 (0.44) | KMT2AMEN1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6840313 | 0.83 | KMT2A (0.44) | KMT2AMEN1MGLLGPR119NPC1 | |
| SCHEMBL3234860 | 0.82 | ALDH1A1 (0.43) | KMT2AMEN1MGLLGPR119NPC1 | |
| SCHEMBL694333 | 0.81 | KMT2A (0.50) | KMT2AMEN1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5136397 | 0.78 | KMT2A (0.46) | KMT2AMEN1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| EP-3401314-B1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2023-11-08 | — | — | EP | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | ARAXES PHARMA LLC (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2019-08-29 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| US-10273207-B2 | Covalent inhibitors of kras G12C | ARAXES PHARMA LLC (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3401314-A1 | COVALENT INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-10111874-B2 | Combination therapies for treatment of cancer | ARAXES PHARMA LLC (US) | 2018-10-30 | — | — | US | disclosed |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2018-06-14 | — | — | US | disclosed |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | ARAXES PHARMA LLC | 2016-06-16 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2016-06-09 | — | — | US | disclosed |
| EP-2970121-A1 | COVALENT INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227978-B2 | Covalent inhibitors of Kras G12C | ARAXES PHARMA LLC (US) | 2016-01-05 | — | — | US | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014152588-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288045-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885 |
| US-20160159738-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885 |
| US-20180162812-A1 | COVALENT INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885 |
| US-10111874-B2 | Combination therapies for treatment of cancer | KRAS, TP53, HRAS | KMT2A 1502/4885MEN1 872/4885CYP3A4 4654/4885 |
| US-20190262342-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KMT2A 1502/4885MEN1 872/4885CYP3A4 4654/4885 |
| US-10919850-B2 | Covalent inhibitors of KRas G12C | KRAS, NRAS, HRAS | KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885 |
| US-20160166571-A1 | COMBINATION THERAPIES FOR TREATMENT OF CANCER | KRAS, TP53, HRAS | KMT2A 1502/4885MEN1 872/4885CYP3A4 4654/4885 |
| US-10273207-B2 | Covalent inhibitors of kras G12C | KRAS, NRAS, HRAS | KMT2A 535/4885MEN1 2271/4885CYP3A4 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.